We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
+7.33%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$123M
AUM Growth
+$7.42M
(+6.4%)
Cap. Flow
+$6.34M
Cap. Flow
% of AUM
5.16%
Top 10 Holdings %
Top 10 Hldgs %
65.43%
Holding
71
New
10
Increased
12
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Direxion Daily Technology Bull 3x ETF
TECL
|
+$1.68M |
| 2 |
Prothena Corp
PRTA
|
+$1.5M |
| 3 |
DocGo
DCGO
|
+$960K |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$794K |
| 5 |
Treace Medical Concepts
TMCI
|
+$622K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$1.12M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$1M |
| 3 |
Elutia
ELUT
|
+$371K |
| 4 |
Progyny
PGNY
|
+$369K |
| 5 |
Coherus Oncology
CHRS
|
+$325K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.88% |
| 2 | Energy | 3.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Ultragenyx Pharmaceutical
RARE
$2.81B
| $673K | 0.55% |
+16,000
| New | +$794K |
|
27
Xencor
XNCR
$1.39B
| $597K | 0.49% |
26,000
+13,700
| +111% | +$315K |
|
28
Kiniksa Pharmaceuticals
KNSA
$4.81B
| $593K | 0.48% |
30,000
| – | – |
|
|
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
| $567K | 0.46% |
67,000
-15,000
| -18% | -$155K |
|
|
30
Alphatec Holdings
ATEC
$1.27B
| $532K | 0.43% |
58,000
-140,000
| -71% | -$1.12M |
|
31
Candel Therapeutics
CADL
$701M
| $521K | 0.42% |
+60,000
| New | +$355K |
|
32
Wave Life Sciences
WVE
$1.1B
| $495K | 0.4% |
40,000
| – | – |
|
33
Inhibrx
INBX
$1.23B
| $494K | 0.4% |
32,110
| – | – |
|
34
Halozyme
HALO
$9.14B
| $478K | 0.39% |
10,000
| – | – |
|
35
Cytokinetics
CYTK
$10.7B
| $470K | 0.38% |
10,000
| – | – |
|
|
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
| $447K | 0.36% |
14,000
| – | – |
|
37
Sarepta Therapeutics
SRPT
$1.78B
| $426K | 0.35% |
3,500
+1,000
| +40% | +$123K |
|
38
Outset Medical
OM
$75.3M
| $409K | 0.33% |
24,584
+23,917
| +3,586% | +$299K |
|
39
Xenon Pharmaceuticals
XENE
$6.38B
| $392K | 0.32% |
10,000
| – | – |
|
|
AXDX
40
DELISTED
Accelerate Diagnostics
AXDX
| $390K | 0.32% |
325,239
| – | – |
|
41
TELA Bio
TELA
$32.2M
| $378K | 0.31% |
+125,000
| New | +$351K |
|
|
SWTX
42
DELISTED
SpringWorks Therapeutics
SWTX
| $361K | 0.29% |
10,000
| – | – |
|
43
uniQure
QURE
$2.73B
| $353K | 0.29% |
20,000
| – | – |
|
44
Pulmonx
LUNG
$57M
| $346K | 0.28% |
+51,000
| New | +$336K |
|
45
Scholar Rock
SRRK
$6.07B
| $346K | 0.28% |
+8,000
| New | +$260K |
|
46
Axsome Therapeutics
AXSM
$11.4B
| $338K | 0.28% |
4,000
| – | – |
|
47
BioCryst Pharmaceuticals
BCRX
$2.32B
| $301K | 0.24% |
40,000
| – | – |
|
48
Atara Biotherapeutics
ATRA
$74.7M
| $293K | 0.24% |
+22,000
| New | +$232K |
|
49
Arvinas
ARVN
$517M
| $288K | 0.23% |
15,000
| – | – |
|
50
Karyopharm Therapeutics
KPTI
$169M
| $284K | 0.23% |
27,989
-3,333
| -11% | -$40.3K |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q4 2024 Portfolio in Review
As of Q4 2024, Birchview Capital held 71 positions worth $123M, up 6.4% from $115M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Birchview Capital deployed $6.34M of net new capital in Q4 2024, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Energy.
On the sell side, the largest reduction was Alphatec Holdings, an estimated $1.12M trimmed.
- Birchview Capital's largest Q4 2024 buy was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.
- Birchview Capital added most to Prothena Corp in Q4 2024, an estimated $1.5M increase.
- Birchview Capital's biggest Q4 2024 reduction was Alphatec Holdings, cutting an estimated $1.12M.
- Birchview Capital fully exited Progyny in Q4 2024, selling an estimated $369K.
- Birchview Capital's ten largest holdings make up 65% of its $123M portfolio in Q4 2024.
- Birchview Capital opened 10 new positions and closed 3 in Q4 2024.
- Birchview Capital's portfolio value rose 6.4% quarter-over-quarter to $123M.
Based on Birchview Capital's 13F filing for Q4 2024, filed 14 Feb 2025.